Healthcare company Tevogen Bio said on Monday that it plans to evaluate its proprietary antigen-specific T cell technology as the potential treatment for COVID-19 and influenza-A patients in partnership with Neal Flomenberg MD from Thomas Jefferson University.
Dr Neal Flomenberg is the chairman of Medical Oncology at Jefferson University in Philadelphia and heads the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Programme. He has developed an approach to bone-marrow transplants that assures that the majority of blood and bone-marrow cancer patients can benefit from this potentially curative treatment.
Through the collaboration, Tevogen will leverage its proprietary immunotherapy platform with Dr Flomenberg's expertise and research prowess to investigate potential treatments for viral infections. Tevogen CEO Ryan Saadi, MD, MPH, is leading the new biotech's efforts.
This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients